ZIPRASIDONE-MEDIS ziprasidone (as hydrochloride) 60 mg capsule blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

ziprasidone hydrochloride, Quantity: 65.16 mg (Equivalent: ziprasidone, Qty 60 mg)

Commercializzato da:

Medis Pharma Pty Ltd

INN (Nome Internazionale):

Ziprasidone hydrochloride

Forma farmaceutica:

Capsule, hard

Composizione:

Excipient Ingredients: colloidal anhydrous silica; magnesium stearate; titanium dioxide; Gelatin; croscarmellose sodium; pregelatinised maize starch

Via di somministrazione:

Oral

Confezione:

60

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy;,as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar I disorder.

Dettagli prodotto:

Visual Identification: size 3 capsule: white body, white cap; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2015-03-05